Activating mutations in RET lead to the cancer syndrome multiple endocrine neoplasia type 2, which is associated with the occurrence of multiple tumours, including the highly metastatic medullary thyroid carcinoma. The gene discussed is RET; the disease is multiple endocrine neoplasia type 2.